1-ethyl-6,7-ethylenedioxy-4-phenyl-3,4-dihydroquinazolin-2(1H)-thione | 243133-86-0

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 1-ethyl-6,7-ethylenedioxy-4-phenyl-3,4-dihydroquinazolin-2(1H)-thione
• 英文别名: 1-ethyl-4-phenyl-3,4,7,8-tetrahydro-[1,4]dioxino[2,3-g]quinazoline-2-thione
• CAS: 243133-86-0
• 化学式: C₁₈H₁₈N₂O₂S
• 分子量: 326.419
• InChiKey: FYFUYIHXTLJSFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  65.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-ethyl-6,7-ethylenedioxy-4-phenyl-3,4-dihydroquinazolin-2(1H)-thione 在 二氧化锰 乙酸乙酯 、 正己烷 作用下， 以 氯仿 为溶剂， 反应 72.0h， 以hexane to give the title compound (35 mg, 46%)的产率得到1-Ethyl-6,7-ethylenedioxy-4-phenylquinazolin-2(1H)-thione
  参考文献：
  名称：

  Substituted 1(2H)-phthalazinones and pharmaceutical compositions thereof

  摘要：

  本发明涉及新型喹唑啉和杂环化合物，其为AMPA受体的拮抗剂或正调节剂，并用于治疗、预防或改善与中风、全局和局部缺血、中枢神经系统创伤、低血糖和手术相关的神经元丧失，以及治疗或改善包括阿尔茨海默病、肌萎缩性侧索硬化症、亨廷顿病、帕金森病和唐氏综合症在内的神经退行性疾病，治疗、预防或改善兴奋性氨基酸过度刺激的不良后果，治疗、预防或改善焦虑、精神病、惊厥、慢性疼痛、青光眼、视网膜炎、尿失禁、肌肉痉挛和诱导麻醉，以及治疗或改善兴奋性氨基酸缺乏引起的不良后果，如精神分裂症、肌阵挛、阿尔茨海默病和营养不良和神经发育不良，并作为认知和学习增强剂。

  公开号：

  US07652006B2

文献信息

• Substituted quinazolines and analogs and use thereof
  申请人：Euro-Celtique S.A.

  公开号：US06465472B1

  公开（公告）日：2002-10-15

  The invention relates to novel quinazolines and heterocycles which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, myoclonus. Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition and learning enhancers.

  该发明涉及新型喹唑啉和杂环化合物，它们是AMPA受体的拮抗剂或正调节剂，用于治疗、预防或改善与中风、全脑和局部缺血、中枢神经系统创伤、低血糖和手术相关的神经元丧失，以及治疗或改善包括阿尔茨海默病、肌萎缩侧索硬化、亨廷顿病、帕金森病和唐氏综合征在内的神经退行性疾病，治疗、预防或改善兴奋性氨基酸过度刺激的不良后果，治疗、预防或改善焦虑、精神病、抽搐、慢性疼痛、青光眼、视网膜炎、尿失禁、肌肉痉挛和诱导麻醉，以及治疗或改善兴奋性氨基酸缺乏的不良后果，如精神分裂症、肌阵挛、阿尔茨海默病和营养不良和神经发育不良，以及作为认知和学习增强剂。
• Substituted quinazolines and analogs and the use thereof
  申请人：Euro-Celtique S.A.

  公开号：US20030033089A1

  公开（公告）日：2003-02-13

  The invention relates to novel quinazolines and heterocycles which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, myoclonus, Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition and learning enhancers.

  本发明涉及新型的喹唑啉和杂环化合物，它们是AMPA受体的拮抗剂或正向调节剂，并用于治疗、预防或改善与中风、全局和局部缺血、中枢神经系统创伤、低血糖和手术相关的神经元丧失，以及治疗或改善包括阿尔茨海默病、肌萎缩性侧索硬化、亨廷顿病、帕金森病和唐氏综合症在内的神经退行性疾病，治疗、预防或改善兴奋性氨基酸过度刺激的不良后果，治疗、预防或改善焦虑、精神病、惊厥、慢性疼痛、青光眼、视网膜炎、尿失禁、肌肉痉挛和诱导麻醉，以及治疗或改善兴奋性氨基酸缺乏的不良后果，如精神分裂症、肌阵挛、阿尔茨海默病和营养不良和神经发育不良，并作为认知和学习增强剂。
• SUBSTITUTED QUINAZOLINES AND ANALOGS AND THE USE THEREOF
  申请人：CoCensys, Inc.

  公开号：EP1066039A1

  公开（公告）日：2001-01-10
• EP1066039A4
  申请人：——

  公开号：EP1066039A4

  公开（公告）日：2003-02-26
• US6465472B1
  申请人：——

  公开号：US6465472B1

  公开（公告）日：2002-10-15